Aventis Typhoid Promotion Cited For Effectiveness Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
A Typhim Vi flashcard suggests the vaccine protects against typhoid without the need for reimmunization, an FDA letter states. The agency also objects to a comparative claim with another typhoid vaccine.
You may also be interested in...
Aventis Rabies Ad Cited By FDA For Lack Of Risk Information
A poster for Imovax and Imogam should be discontinued because it does not mention adverse events, CBER says. The ad also implies that other products are not available, the agency’s letter states.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).